MikkaelA.SekeresMD

PubMed

• CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) ...
  Yazan Madanat, Michael R Savona, Mikkael A Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Doughert...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
• Combining lenalidomide with erythropoiesis stimulating agents: a party of one.
  Chandhok, N., Sekeres, M.> ;Leukemia. 2024 Mar 1
• Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia.
  Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Laila Terkawi, Hussein Awada, Olisaemeka D Ogbue, Ramsha Ahmed, Simona Pagliuca, Hassan Awada, Yasuo Kubota, Mi...> ;Nature Communications. 2024 Feb 8
• 4 citations
  Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, ra...
  Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M., Savona, M., Madanat, Y., Díez-Campelo, M., Valcárcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L...> ;Lancet. 2024 Jan 20
• 1 citations
  A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
  Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litz...> ;Leukemia. 2024 Jan 1
• 4 citations
  Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
  Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
• 3 citations
  Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
  Shallis, R., Daver, N., Altman, J., Komrokji, R., Pollyea, D., Badar, T., Bewersdorf, J., Bhatt, V., de Botton, S., de la Fuente Burguera, A., Carraway, H., Desai, P.,...> ;The Lancet. Haematology. 2023 Sep 1
• 3 citations
  Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
  Mikkael A Sekeres, Pau Montesinos, Jan Novak, Jianxiang Wang, Deepa Jeyakumar, Benjamin Tomlinson, Jiri Mayer, Erin Jou, Tadeusz Robak, David C Taussig, Hervé Dombret,...> ;Leukemia. 2023 Oct 1
• Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
  Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
• 2 citations
  Molecular patterns identify distinct subclasses of myeloid neoplasia.
  Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Laila Terkawi, Hussein Awada, Olisaemeka D Ogbue, Ramsha Ahmed, Simona Pagliuca, Hassan Awada, Yasuo Kubota, Mi...> ;Nature Communications. 2023 May 30
• 3 citations
  Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
  Gregory A Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wa...> ;Blood Advances. 2023 Jul 25
• Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
  Sudipto Mukherjee, Weichuan Dong, Nicholas K Schiltz, Kurt C Stange, Jennifer Cullen, Aaron T Gerds, Hetty E Carraway, Abhay Singh, Anjali S Advani, Mikkael A Sekeres,...> ;The Oncologist. 2023 Oct 3
• 35 citations
  Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-...
  Harry P Erba, Pau Montesinos, Hee-Je Kim, Elżbieta Patkowska, Radovan Vrhovac, Pavel Žák, Po-Nan Wang, Tsvetomir Mitov, James Hanyok, Yasser Mostafa Kamel, Jaime E Con...> ;Lancet. 2023 May 13
• 5 citations
  STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
  Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini> ;Future Oncology. 2023 Mar 1
• Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in...
  Benjamin Tomlinson, Marcos de Lima, Christopher R Cogle, Michael A Thompson, David L Grinblatt, Daniel A Pollyea, Rami S Komrokji, Gail J Roboz, Michael R Savona, Mikk...> ;Transplantation and Cellular Therapy. 2023 Jul 1
• Raising the bar for lower-risk myelodysplastic syndromes.
  Sangeetha Venugopal, Mikkael A Sekeres> ;Leukemia & Lymphoma. 2023 Jun 1
• 3 citations
  Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
  Amy E DeZern, Johannes B Goll, R Coleman Lindsley, Rafael Bejar, Steffanie H Wilson, Donnie Hebert, Joachim Deeg, Ling Zhang, Steven Gore, Tareq Al Baghdadi, Jaroslaw ...> ;Blood Advances. 2023 Jul 25
• 6 citations
  Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1International Workshop on MDS (iwMDS) Of t...
  Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M Brunner, Rena Buckstein, Hetty E Carraway, Jane E Churpek, Naval G Daver, ...> ;Blood Reviews. 2023 Jul 1
• Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia.
  Richard M Stone, Mikkael A Sekeres, Altman, J.> ;Blood Advances. 2023 Dec 26
• 28 citations
  Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
  Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Adès, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E Carraway, Naval...> ;Blood. 2023 Apr 27
• 9 citations
  Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes.
  Tariq Kewan, Waled Bahaj, Arda Durmaz, Mai Aly, Hetty E Carraway, Mikkael A Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P Maciejewski, Olisaemeka D Ogbue> ;Blood. 2023 Apr 6
• 3 citations
  Considerations for Drug Development in Myelodysplastic Syndromes.
  Mikkael A Sekeres, Nina Kim, Amy E DeZern, Kelly J Norsworthy, Jacqueline S Garcia, R Angelo de Claro, Marc R Theoret, Emily Y Jen, Lori A Ehrlich, Amer M Zeidan, Rami...> ;Clinical Cancer Research. 2023 Jul 14
• 5 citations
  An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
  Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
• 8 citations
  Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
  Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M Totiger, David Coffey, ...> ;Blood. 2023 May 11
• 1 citations
  Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.
  Joshua F Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J Fram, Douglas V Faller, Mehul Dalal, Lionel Ades, Mikka...> ;Haematologica. 2023 Apr 1
• Join now to see all

Journal Articles

• Germline Loss of Function SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes  
  Samuel Li, Mikkael A Sekeres, Jaroslaw P Maciejewski, Rabi Hanna, Blood
• Relative Survival Following Response to 7 + 3 Versus Azacytidine Is Similar in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes: An Analysis of Four SWOG...  
  Sucha Nand, Mikkael A Sekeres, Nature
• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Join now to see all

Abstracts/Posters

• Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor ExpansionClinically Relevant Abstract
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and My...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate PotentialClinically Relevant Abstract
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hematologic Improvement_Neutrophil and _Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspate...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving I...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patient...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (...
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in AdultsClinically Relevant Abstract
  Mikkael A. Sekeres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Special Education Session on ASH Clinical Practice Guidelines on Acute Myeloid Leukemia in Older Adults 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Myelodysplastic Syndromes: From Mild-Mannered to Lurking Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Meeting Tips: Giving a Scientific Presentation, Being a Good Discussant and Asking a Question in the Aisle 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Late-Breaking Abstracts Session 
  60th American Society of Hematology Annual Meeting - 12/4/2018
• The Story Is the Story: Using Narrative Medicine to Cure Disease 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of CancerClinically Relevant Abstract 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Blood Drops: Telling It Like It Is: Essays About Medicine 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Watching My Patient Die, Remotely 
  American Society of Hematology (ASH), New York, New York - 2/3/2012
• Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic mye... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Resolutions of a Cancer Doctor 
  American Society of Hematology (ASH), Austin, Texas - 1/20/2012
• Resolutions of a Cancer Doctor 
  American Society of Hematology (ASH), Las Vegas, Nevada - 1/27/2012
• Join now to see all